Lamiaa El-Shennawy, Andrew D Hoffmann, Nurmaa Khund Dashzeveg, Kathleen M McAndrews, Paul J Mehl, Daphne Cornish, Zihao Yu, Valerie L Tokars, Vlad Nicolaescu, Anastasia Tomatsidou, Chengsheng Mao, Christopher J Felicelli, Chia-Feng Tsai, Carolina Ostiguin, Yuzhi Jia, Lin Li, Kevin Furlong, Jan Wysocki, Xin Luo, Carolina F Ruivo, Daniel Batlle, Thomas J Hope, Yang Shen, Young Kwang Chae, Hui Zhang, Valerie S LeBleu, Tujin Shi, Suchitra Swaminathan, Yuan Luo, Dominique Missiakas, Glenn C Randall, Alexis R Demonbreun, Michael G Ison, Raghu Kalluri, Deyu Fang, Huiping Liu
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the pandemic of the coronavirus induced disease 2019 (COVID-19) with evolving variants of concern. It remains urgent to identify novel approaches against broad strains of SARS-CoV-2, which infect host cells via the entry receptor angiotensin-converting enzyme 2 (ACE2). Herein, we report an increase in circulating extracellular vesicles (EVs) that express ACE2 (evACE2) in plasma of COVID-19 patients, which levels are associated with severe pathogenesis...
January 20, 2022: Nature Communications